Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$2.88 USD
+0.09 (3.23%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.89 +0.01 (0.35%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum B VGM
Harvard Bioscience (HBIO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.88 | $7.00 | $6.75 | 146.59% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Harvard Bioscience comes to $6.88. The forecasts range from a low of $6.75 to a high of $7.00. The average price target represents an increase of 146.59% from the last closing price of $2.79.
Analyst Price Targets (2 )
Broker Rating
Harvard Bioscience currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/3/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
3/18/2024 | Singular Research | Frank C Dilorenzo | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $6.88 |
LT Growth Rate | NA |
Industry | Instruments - Scientific |
Industry Rank by ABR | 94 of 253 |
Current Quarter EPS Est: | 0.05 |
HBIO FAQs
Harvard Bioscience, Inc. (HBIO) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Harvard Bioscience, Inc. (HBIO) is $6.88. The current on short-term price targets is based on 1 reports.
The forecasts for Harvard Bioscience, Inc. (HBIO) range from a low of $6.75 to a high of $7. The average price target represents a increase of $138.89 from the last closing price of $2.88.
The current UPSIDE for Harvard Bioscience, Inc. (HBIO) is 138.89%
Based on short-term price targets offered by two analysts, the average price target for Harvard Bioscience comes to $6.88. The forecasts range from a low of $6.75 to a high of $7.00. The average price target represents an increase of 146.59% from the last closing price of $2.79.